» Articles » PMID: 21128227

Detection of Circulating Tumor Cells As a Prognostic Factor in Patients Undergoing Radical Surgery for Non-small-cell Lung Carcinoma: Comparison of the Efficacy of the CellSearch Assay™ and the Isolation by Size of Epithelial Tumor Cell Method

Overview
Journal Int J Cancer
Specialty Oncology
Date 2010 Dec 4
PMID 21128227
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

Comparison of the efficacy of different enrichment methods for detection of circulating tumor cells (CTCs) before radical surgery is lacking in non-small-cell lung carcinoma (NSCLC) patients. Detection and enumeration of CTCs in 210 consecutive patients undergoing radical surgery for NSCLC were evaluated with the CellSearch Assay™ (CS), using the CellSearch Epithelial Cell Kit, and by the isolation by size of epithelial tumor (ISET) method, using double immunolabeling with anti-cytokeratin and anti-vimentin antibodies. CTCs were detected in 144 of 210 (69%) patients using CS and/or ISET and in 104 of 210 (50%) and 82 of 210 (39%) patients using ISET and CS, respectively. Using ISET, 23 of 210 (11%) patients had vimentin-positive cells with cytological criteria of malignancy. Disease-free survival (DFS) was worse for patients with CTCs compared to patients without CTCs detected by CS alone (p < 0.0001; log rank = 30.59) or by ISET alone (p < 0.0001; log rank = 33.07). The presence of CTCs detected by both CS and ISET correlated even better with shorter DFS at a univariate (p < 0.0001; log rank = 42.15) and multivariate level (HR, 1.235; 95% CI, 1.056-1.482; p < 0.001). CS and ISET are complementary methods for detection of CTCs in preoperative radical surgery for NSCLC. CTC detection in resectable NSCLC patients using CS and/or ISET could be a prognostic biomarker of great interest and may open up new avenues into improved therapeutic strategies for lung carcinoma patients.

Citing Articles

EpCAM Signaling in Oral Cancer Stem Cells: Implications for Metastasis, Tumorigenicity, and Therapeutic Strategies.

Chang C, Tsai C, Tsai F, Chu T, Hsu P, Kuo C Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996844 PMC: 11854592. DOI: 10.3390/cimb47020123.


The capture of circulating tumor cells by Labyrinth system as a tool for early stage lung cancer detection.

Jin P, Li H, Xie M, Tang J, Zou S, Wang R Front Oncol. 2024; 14:1474015.

PMID: 39540154 PMC: 11557529. DOI: 10.3389/fonc.2024.1474015.


Unveiling the dynamics of circulating tumor cells in colorectal cancer: from biology to clinical applications.

Dompe C, Chojnowska A, Ramlau R, Nowicki M, Alix-Panabieres C, Budna-Tukan J Front Cell Dev Biol. 2024; 12:1498032.

PMID: 39539964 PMC: 11557528. DOI: 10.3389/fcell.2024.1498032.


Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study.

Sugai K, Mori T, Bilal T, Furukawa A, Sekine Y, Kobayashi N BMC Cancer. 2024; 24(1):1291.

PMID: 39425044 PMC: 11488178. DOI: 10.1186/s12885-024-12945-9.


CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

Portella L, Bertolini G, Guardascione G, Di Febbraro D, Ierano C, DAlterio C Heliyon. 2024; 10(15):e35524.

PMID: 39170328 PMC: 11336720. DOI: 10.1016/j.heliyon.2024.e35524.